Narayana Hrudayalaya Ltd

- Current Capex is a mix of debt (about 80%) and internal accruals funding, with long-term loans of 10-20 years. - Brownfield capacity addition mainly involves existing hospitals, capitalizing work-in-progress and settling bills, with some spillover expected to next quarters. - Greenfield projects involve hospital construction, with typical timelines of 2-2.5 years for construction and 6-9 months for licensing/fitment, totaling around 3 years to operational startup. - Capex focus shifted from Health City expansion (extra tower) to multiple city-wide projects like HSR, Central Bangalore, and South Bangalore. - Expansion includes adding beds in Howrah, Barasat, and other regions, but no aggressive addition unless there is a business case. - IRR target for brownfield projects is above 15%. - Future strategic investments include expanding primary health clinics (50 clinics target in the next year) and continued growth in Cayman with new hospital operations and integrated care products. - Ongoing exploration for further regional/international expansion, albeit with high thresholds for new markets.

- Organic growth trajectory is established with reasonable, steady growth expected over time. - Revenue growth will be supported by organic expansion and selective inorganic augmentations. - Upcoming quarters will see uplift from new hospital capacity in Cayman and added capacity in MMRHL hospital. - Clinics and insurance businesses are focusing on scaling within core cities, with 50 clinics targeted next year (mainly Bangalore and Kolkata). - Expansion will focus on smaller hospitals (200-250 beds) clustered across cities to improve patient access rather than large flagship hospitals beyond one per city. - Growth is concentrated in 2-3 key cities over 5-7 years with potential for future rollouts based on proven success. - Insurance subsidiary to scale moderately with adequate capitalization; major spend expected on clinics rather than insurance unit. - No aggressive price strategy, so ARPP and revenue growth expected to be in line with historical trends.

- Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18). - Improvement in EBITDA and margins anticipated, especially from new hospitals such as Gurugram and Dharamshala, with Q4 expected to be stronger (Page 4). - Cayman facility margins showed sequential improvement; further margin enhancement expected as full services commission by March (Pages 3-4). - ARPP growth projected to be moderate, reflecting a non-aggressive pricing strategy, with uplift from Cayman and capacity expansions (Page 19). - Dividend strategy to continue consistently, providing reasonable cash returns (Page 24). - Clinic and insurance verticals are growth engines but expected losses and burn will be controlled, with breakeven around 18 months and total investment capped at INR 400-500 crores over 2-3 years (Pages 14-15). - Target IRR on new projects is upwards of 15%, with 3-year timeline to operationalize expansions (Page 12).

The transcript provided from the document "1273196.pdf" does not contain explicit information regarding the company's current or expected order book or pending orders. The discussion primarily revolves around operational performance, expansion plans, clinic openings, hospital throughput, capital expenditure funding, and geographical focus areas. Topics also include digital initiatives, patient processing benchmarks, Cayman Islands operations, and financial controls but do not specify order book details. If you need specific data on order books or pending orders, such details might be in a different section or financial report not included here.

- The company plans to fund Capex through a mix of debt and internal accruals, with about 80% of project finance coming from banks via long-term loans (10-20 years). - They are comfortable with Debt-EBITDA levels up to around 3 and expect to reach that level by the end of the 4th year if all planned projects proceed. - As new hospitals become EBITDA positive, the Debt-EBITDA ratio is expected to decline, allowing for potential further phases of expansion. - There is no explicit mention of raising equity or issuing bonus shares at this time; management considers current priorities and performance more important. - The focus remains on conservative borrowing within serviceability limits and maintaining dry powder for special situations.